Zacks: Analysts Expect Abeona Therapeutics Inc (ABEO) Will Announce Earnings of -$0.31 Per Share

Equities analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report earnings per share of ($0.31) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Abeona Therapeutics’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.38). Abeona Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 72.2%. The business is scheduled to report its next quarterly earnings report on Friday, May 10th.

On average, analysts expect that Abeona Therapeutics will report full-year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.80) to ($1.25). For the next year, analysts anticipate that the business will report earnings of ($1.70) per share, with EPS estimates ranging from ($2.11) to ($1.24). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Abeona Therapeutics.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Cantor Fitzgerald set a $29.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 19th. ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Abeona Therapeutics in a report on Thursday, February 21st. Finally, BidaskClub cut Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, February 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Abeona Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.00.



ABEO traded down $0.79 during midday trading on Tuesday, hitting $7.52. The company’s stock had a trading volume of 578,904 shares, compared to its average volume of 451,891. The stock has a market capitalization of $360.58 million, a price-to-earnings ratio of -6.32 and a beta of 1.93. Abeona Therapeutics has a 52-week low of $6.26 and a 52-week high of $22.00.

A number of institutional investors have recently added to or reduced their stakes in the stock. Parkside Advisors LLC lifted its position in Abeona Therapeutics by 16.0% during the 4th quarter. Parkside Advisors LLC now owns 14,530 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 2,000 shares in the last quarter. SG Americas Securities LLC lifted its position in Abeona Therapeutics by 23.7% during the 4th quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 4,351 shares in the last quarter. Geode Capital Management LLC lifted its position in Abeona Therapeutics by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock worth $2,436,000 after acquiring an additional 6,826 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in Abeona Therapeutics by 247.2% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 7,258 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its position in Abeona Therapeutics by 9.4% during the 3rd quarter. Allianz Asset Management GmbH now owns 110,649 shares of the biopharmaceutical company’s stock worth $1,416,000 after acquiring an additional 9,465 shares in the last quarter. 67.93% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.